221 Diagnostic utility of molecular and imaging biomarkers 2 Solitary nodule Solid nodule Hypoechogeneity 6L]H FP Taller-than-wide shape Absence of halo ,UUHJXODU PDUJLQ Intranodular vascularisation 0LFURFDOFL¿FDWLRQV 0DFURFDOFL¿FDWLRQV all Bethesda III Bethesda IV all Bethesda III Bethesda IV all Bethesda III Bethesda IV all Bethesda III Bethesda IV all Bethesda III Bethesda IV all Bethesda III Bethesda IV all Bethesda III Bethesda IV all Bethesda III Bethesda IV all Bethesda III Bethesda IV all Bethesda III Bethesda IV 1,569 600 699 3,042 1,518 784 4,276 1,601 1,157 445 0 386 2,129 1,256 637 1,533 694 359 3,969 1,601 947 2,835 1,030 541 4,027 1,331 994 2,275 1,607 172 number of studies ni 13 3 6 27 9 8 33 10 10 6 0 5 15 8 4 13 4 3 28 10 8 21 6 5 31 9 8 18 10 2 negative likelihood ratio (95% CI) 0 1.0 0.50 0.25 0.75 0.95 (0.73-1.25) n.a.c. 1.02 (0.58-1.78) 0.58 (0.47-0.71) 0.48 (0.34-0.69) 0.88 (0.62-1.25) 0.61 (0.53-0.71) 0.53 (0.38-0.73) 0.68 (0.54-0.86) 0.89 (0.79-1.00) n.a. 0.89 (0.79-1.00) 0.74 (0.67-0.81) 0.65 (0.59-0.71) 0.81 (0.74-0.89) 0.67 (0.49-0.93) 0.47 (0.21-1.03) 0.92 (0.39-2.15) 0.65 (0.56-0.75) 0.52 (0.44-0.62) 0.81 (0.71-0.92) 0.74 (0.60-0.92) 0.82 (0.58-1.15) 0.72 (0.54-0.95) 0.75 (0.67-0.84) 0.70 (0.60-0.82) 0.64 (0.39-1.06) 0.97 (0.91-1.04) 0.98 (0.91-1.06) 0.89 (0.62-1.26) 1.25 81.7% n.a.c. 91.2% 44.9% 25.0% 22.6% 80.6% 93.0% 71.5% 0.0% n.a. 0.0% 73.0% 30.2% n.a.c. 90.6% n.a.c. n.a.c. 95.5% 55.5% 75.6% 87.1% 90.3% 78.5% 69.4% 38.9% 89.9% 45.3% 38.4% n.a.c. i2
RkJQdWJsaXNoZXIy MTk4NDMw